Table 1.
Summary of antitumor activity of TH-302 monotherapy, gemcitabine and nab-paclitaxel doublet and gemcitabine, nab-paclitaxel and TH-302 triplet in the Hs766t, MIA PaCa-2, PANC-1 and BxPC-3 PDAC xenograft models
| TV 1000 mm3 as Endpoint |
||||||
|---|---|---|---|---|---|---|
| Model | Group | TGI | TGD1000 (vs. Vehicle) | CR Rate | MT (day) | ILS |
| Hs766t | Vehicle | 0 | 15 | |||
| TH-302 | 82% | 47 | 0 | 60*,a | 297% | |
| G + nP Doublet | 85% | 35 | 0 | 50* | 230% | |
| G + nP + T Triplet | 86%* | 53 | 10% | 65*,a,b | 330% | |
| MIA PaCa-2 | Vehicle | 0 | 27 | |||
| TH-302 | 27% | 6 | 0 | 34 | 26% | |
| G + nP Doublet | 107%* | 23 | 30% | 57* | 111% | |
| G + nP + T Triplet | 120%*,a,b | >39 | 90% | 82*,b | 204% | |
| PANC-1 | Vehicle | 0 | 21 | |||
| TH-302 | 45% | 7 | 10% | 31 | 48% | |
| G + nP Doublet | 107%* | 34 | 60% | 60* | 186% | |
| G + nP + T Triplet | 110%*,a,b | >34 | 100% | 71*,b | 238% | |
| BxPC-3 | Vehicle | 0 | 16 | |||
| TH-302 | 43% | 11 | 0 | 24 | 52% | |
| G + nP Doublet | 85%* | 16 | 0 | 29* | 84% | |
| G + nP + T Triplet | 87%*,b | 18 | 0 | 35*,b | 123% | |
TGI: Tumor Growth Inhibition; TGD1000: Tumor Growth Delay compared to Vehicle reaching the size of 1000 mm3; CR: complete response, the disappearance of measurable tumor mass or if measured tumor volume was less than 100 mm3 after initiating therapy; MT: Median Time to reach the size of 1000 mm3; ILS: Increased Life Span; *, p < 0.05 compared with Vehicle; a, p < 0.05 compared with G + nP Doublet; b, p < 0.05 compared with T monotherapy.